Cencora's stock price fell to $287.06 over the past six months, a 15.8% decline that contrasts with the S&P 500's 6.2% gain, partly due to softer quarterly results. The company, formerly AmerisourceBergen, generated $328.7 billion in revenue over the past 12 months, giving it significant scale and negotiating leverage with suppliers. Its earnings per share grew at a 14.6% compound annual rate over five years, outpacing its 10.9% annualized revenue growth, while its five-year average return on invested capital reached 50.4%, placing it among the top healthcare firms. The stock now trades at 15.3 times forward earnings.
Cencora Inc.Stock fell 15.8% over six months despite strong fundamentals, partly due to softer quarterly results.